Abstract:BackgroundThromboembolic events are leading causes of mortality and morbidity all over the world. Tongmai (TM) is a botanical drug with valid clinical efficacy and safety in the management of thrombosis and ischemic cardiovascular diseases, however, its active compounds and underlying mechanism are largely unclear.PurposeTo investigate the endogenous effects, therapeutic mechanism and active compounds of TM in thrombus formation.Study designCombined with transgenic zebrafish models and high-content imaging system, this study evaluated the endogenous antithrombotic effects of TM and screened for the active compounds.MethodsThe PHZ-induced thrombotic model in erythrocytes or platelets labeled transgenic zebrafish were established, to dynamically evaluate the antithrombotic effects of TM. The oxidative damage levels were analyzed by specific fluorescent probes, and the expression levels of key factors in coagulation cascades and platelet activation were examined by QPCR. TM were dissected into fractions by reverse phase chromatography and subsequently screened for their antithrombotic effects in the transgenic fish models. The compounds of the active TM fraction were then analyzed by UPLC-Q-TOF analysis and further verified for their antithrombotic effects and mechanisms.ResultsIn PHZ-induced zebrafish thrombotic model, TM incubation markedly increased cardiac blood flow, decreased peripheral erythrocytes aggregation, and recovered peripheral platelet circulation. Besides, the levels of oxidative stress and lipid peroxidation were increased in the PHZ-induced thrombotic fish, which were greatly decreased by TM treatment. Moreover, TM significantly reduced the expression of coagulation factor II (thrombin) and the downstream fibrinogen. In order to identify the active compounds of TM, four fractions were separated from the extract by reverse phase chromatography, which were subsequently screened for their antithrombotic effects in the fish model. As a result, fraction 4 showed the strongest effect in inhibiting thrombosis. Finally, through UPLC-Q-TOF analysis and endogenous screening, cryptotanshione was identified as the main active compound with antithrombotic effects.ConclusionOur study demonstrated the endogenous antithrombotic effects of TM, which is possibly mediated by inhibiting oxidative stress and coagulation cascade. Cryptotanshione was identified as a major compound with antithrombotic activity and is a promising candidate for novel antithrombotic therapy.

Research advances of natural thrombin inhibitors

The Research Progress of Direct Thrombin Inhibitors

Factor Ⅺ-a promising anticoagulation target

Discovering peptide inhibitors of thrombin as a strategy for anticoagulation

Therapeutic effects and molecular mechanisms of natural products in thrombosis

Theaflavin: a Natural Candidate to Restrain Thrombosis

Identification of Cryptotanshinone from Tongmai to Inhibit Thrombosis in Zebrafish Via Regulating Oxidative Stress and Coagulation Cascade.

Research Progress of Low Molecular Weight Heparin

Thrombolysis of plasmin and its derivatives:research advances

Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review

Mechanisms of thrombosis and research progress on targeted antithrombotic drugs

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

[Recurrent digestive hemorrhage after pancreatic duct-jejunum anastomosis].

Discovery and characterization of panaxatriol as a novel thrombin inhibitor from Panax notoginseng using combination of computational and experimental approach.

Hemorrhagic fibrino(geno)lytic enzymes from snake venom

Pharmaceutical methods of identifying fibrinolytic activity

Regulation of Thrombin Activity with a Bifunctional Aptamer and Hemin: Development of a New Anticoagulant and Antidote Pair.

Thrombin and Thrombin‐Incorporated Biomaterials for Disease Treatments

Discovery of Novel, Potent, Isosteviol-Based Antithrombotic Agents

Theranostic Probes for Targeted Immunotherapy

Discovery and development of Factor Xa inhibitors (2015-2022)